Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04816721 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate EDP 938 Regimens in Children With RSV
A Phase 2 study of Respiratory Syncytial Virus (RSV), sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT04816721: Completed Phase 2 study of Respiratory Syncytial Virus (RSV), sponsored by Enanta Pharmaceuticals.
NCT04816721 is a Phase 2 study of Respiratory Syncytial Virus (RSV) that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 99 participants, below the 6,747-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04816721, a Phase 2 study of Respiratory Syncytial Virus (RSV), has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
Primary Outcome
Plasma concentrations of EDP-938 were assessed at the designated time points.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP-938
Study Locations (20)
California
- Memorial Care Miller Children's and Women's Hospital - Long Beach
- University of California Los Angeles (UCLA) - Los Angeles
- University of California Davis - Sacramento
Louisiana
- MedPharmics - Lafayette - Lafayette
- LSU Health - Shreveport
- Willis-Knighton Health System - Shreveport
Other
- Hospital Interzonal Dr Jose Penna - Bahía Blanca
- Clínica Privada del Sol - Buenos Aires
- Instituto Medico Rio Cuarto - Río Cuarto
Florida
- Nemours Children's Hospital - Orlando
- South Tampa Center for Advanced Healthcare - Tampa
Texas
- Driscoll Children's Hospital - Corpus Christi
- Children's Health Specialty Center Dallas Campus - Dallas
Idaho
- Rexburg Pediatrics - Rexburg
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Kentucky
- Norton Children's Research Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2024-08-19 |
| Phase | Phase 2 |
What the finished NCT04816721 record still lists
NCT04816721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 6,747-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04816721 names 20 study sites across 12 states, led by California, Louisiana, Other.
Frequently Asked Questions
What is clinical trial NCT04816721 about?
NCT04816721 is a clinical study titled "A Study to Evaluate EDP 938 Regimens in Children With RSV". A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
What is the current status of trial NCT04816721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2022-04-26. Estimated completion is 2024-08-19.
What conditions does trial NCT04816721 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT04816721?
The interventions under investigation include: Placebo (DRUG), EDP-938 (DRUG).
Who is sponsoring clinical trial NCT04816721?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04816721 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus (RSV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04816721's enrollment target sits among peer trials
99 10th of 11 higher than 2 of 11 other Respiratory Syncytial Virus (RSV) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus (RSV) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
RECRUITING · Phase 2
-
RSV Vaccine Pregnancy Registry
RECRUITING
-
Systems Biological Analysis of Immune Responses to RSV Vaccine
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
ACTIVE NOT RECRUITING · Phase 1
-
Transplacental Transmission of RSV (TTRSV)
ACTIVE NOT RECRUITING
-
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI